Eirion Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.eirionthera.com
AI-09 In Subjects With Glabellar Lines, GL-101
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Eirion Therapeutics Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT05565950
- Locations
- 🇺🇸
Eirion Research Site, Miami, Florida, United States
ET-01 in Subjects With Lateral Canthal Lines, LCL-210
Phase 2
Completed
- Conditions
- Lateral Canthal Lines, LCLCrow's Feet
- Interventions
- Biological: Vehicle
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eirion Therapeutics Inc.
- Target Recruit Count
- 280
- Registration Number
- NCT04985916
- Locations
- 🇺🇸
Eirion Research Site, Norfolk, Virginia, United States
ET-01 in Subjects With Lateral Canthal Lines, LCL-209
Phase 2
Completed
- Conditions
- Lateral Canthal Lines, LCLCrow's Feet
- Interventions
- Biological: VehicleBiological: botulinum toxin, Type A
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- Eirion Therapeutics Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT03912805
- Locations
- 🇺🇸
Virginia Clinical Research, Inc., Norfolk, Virginia, United States
🇺🇸Yardley Dermatology Associates, Yardley, Pennsylvania, United States
🇺🇸Synexis, Inc., Pinellas Park, Florida, United States
ET-01 in Subjects With Lateral Canthal Lines, LCL-208
Phase 2
Completed
- Conditions
- Lateral Canthal LinesCrow's Feet
- Interventions
- Biological: VehicleBiological: botulinum toxin, Type A
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Eirion Therapeutics Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT03839693
- Locations
- 🇺🇸
Synexus, Inc., Pinellas Park, Florida, United States
🇺🇸Virginia Clinical Research, Inc., Norfolk, Virginia, United States
🇺🇸Baumann Cosmetic & Research Institute, Miami, Florida, United States
ET-01 in Subjects With Lateral Canthal Lines, LCL-207
Phase 2
Completed
- Conditions
- Lateral Canthal LinesCrow's Feet
- Interventions
- Biological: VehicleBiological: botulinum toxin, Type A
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Eirion Therapeutics Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT03655691
- Locations
- 🇺🇸
Radiant Research, Inc., Pinellas Park, Florida, United States
🇺🇸Dermatology NOLA Inc., Metairie, Louisiana, United States
🇺🇸Baumann Cosmetic & Research Institute, Miami, Florida, United States
ET-01 in Subjects With Lateral Canthal Lines
Phase 2
Completed
- Conditions
- Crow's FeetLateral Canthal Lines
- Interventions
- Biological: VehicleBiological: botulinum toxin, Type A
- First Posted Date
- 2017-10-31
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Eirion Therapeutics Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03326856
- Locations
- 🇺🇸
Cary Skin Care, Cary, North Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath